Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: John M. Timmerman, Charles Herbaux, Vincent Ribrag, Andrew D. Zelenetz, Roch Houot, Sattva S. Neelapu, Theodore F. Logan, Izidore S. Lossos, Walter J. Urba, Gilles Salles, Radhakrishnan Ramchandren, Caron A. Jacobson, John E. Godwin, Cecilia Carpio, Deanne Lathers, Yali Liu, Jaclyn Neely, Satyendra Suryawanshi, Yoshinobu Koguchi, Ronald Levy
Médium: Artigo
Jazyk:angličtina
Vydáno: 2020
On-line přístup:https://doi.org/10.1002/ajh.25757
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25757
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1002/ajh.25757
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25757

Podobné jednotky